Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer.
Enolase-1
Immunohistochemistry
MBP-1
Ovarian cancer
Wnt signaling
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
08
2020
revised:
28
09
2020
accepted:
05
10
2020
pubmed:
18
10
2020
medline:
18
10
2020
entrez:
17
10
2020
Statut:
ppublish
Résumé
Enolase-1, primarily known for its role in glucose metabolism, is overexpressed in various cancer entities. In contrast its alternative spliced nuclear isoform MBP-1 acts as a tumor suppressor. The aim of this study is to analyze the prognostic impact of Enolase-1/ MBP-1 and its functional significance in epithelial ovarian cancer (EOC). By immunohistochemistry, Enolase-1 staining was examined in 156 EOC samples. Evaluation of Enolase-1 staining was conducted in the nucleus and the cytoplasm using the semi-quantitative immunoreactive score. Expression levels were correlated with clinical and pathological parameters as well as with overall survival to assess for prognostic impact. Cytoplasmic and nuclear Enolase-1 expression did not show a significant difference between the histological subtypes (p = 0.1). High nuclear Enolase-1/ MBP-1 staining negativly correlated with the tumor grading (p<0.001; Cc= -0.318). Cytoplasmic Enolase-1 did not correlate with clinicopathological data. Higher nuclear Enolase-1/ MBP-1 staining was detected in low-grade serous cancer cases compared to high-grade ones (median IRS 3 (range 0-8) vs. median IRS 2 (range 0-4), p<0.001). Nuclear Enolase-1/ MBP-1 expression correlated with the Wnt signaling markers membranous beta-catenin (p = 0.007; Cc=0.235), serine residue 9-phosphorylated glycogen synthase kinase 3 beta (p<0.001; Cc=0.341) and snail/slug (p = 0.004; Cc= -0.257). High nuclear Enolase-1/ MBP-1 expression was associated with improved overall survival (88.6 vs. 33.1 months, median; p = 0.013). Additional knowledge of Enolase-1/ MBP-1 as a biomarker and its interactions within the Wnt signaling pathway and epithelial-mesenchymal transition potentially improve the prognosis of therapeutic approaches in EOC.
Sections du résumé
BACKGROUND
BACKGROUND
Enolase-1, primarily known for its role in glucose metabolism, is overexpressed in various cancer entities. In contrast its alternative spliced nuclear isoform MBP-1 acts as a tumor suppressor. The aim of this study is to analyze the prognostic impact of Enolase-1/ MBP-1 and its functional significance in epithelial ovarian cancer (EOC).
METHODS
METHODS
By immunohistochemistry, Enolase-1 staining was examined in 156 EOC samples. Evaluation of Enolase-1 staining was conducted in the nucleus and the cytoplasm using the semi-quantitative immunoreactive score. Expression levels were correlated with clinical and pathological parameters as well as with overall survival to assess for prognostic impact.
RESULTS
RESULTS
Cytoplasmic and nuclear Enolase-1 expression did not show a significant difference between the histological subtypes (p = 0.1). High nuclear Enolase-1/ MBP-1 staining negativly correlated with the tumor grading (p<0.001; Cc= -0.318). Cytoplasmic Enolase-1 did not correlate with clinicopathological data. Higher nuclear Enolase-1/ MBP-1 staining was detected in low-grade serous cancer cases compared to high-grade ones (median IRS 3 (range 0-8) vs. median IRS 2 (range 0-4), p<0.001). Nuclear Enolase-1/ MBP-1 expression correlated with the Wnt signaling markers membranous beta-catenin (p = 0.007; Cc=0.235), serine residue 9-phosphorylated glycogen synthase kinase 3 beta (p<0.001; Cc=0.341) and snail/slug (p = 0.004; Cc= -0.257). High nuclear Enolase-1/ MBP-1 expression was associated with improved overall survival (88.6 vs. 33.1 months, median; p = 0.013).
CONCLUSION
CONCLUSIONS
Additional knowledge of Enolase-1/ MBP-1 as a biomarker and its interactions within the Wnt signaling pathway and epithelial-mesenchymal transition potentially improve the prognosis of therapeutic approaches in EOC.
Identifiants
pubmed: 33069100
pii: S1936-5233(20)30402-2
doi: 10.1016/j.tranon.2020.100910
pmc: PMC7569221
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100910Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Thomas Kolben holds stock of Roche AG and his relative is employed at Roche AG. Anna Hester has received a research grant from the “Walter Schulz” foundation and advisory board, speech honoraria and travel expenses from Roche and Pfizer. Alexander Burges has received advisory board and honoraria from AstraZeneca, Clovis, Roche and Tesaro. Research support, advisory board, honoraria, and travel expenses from AstraZeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro, Teva have been received by Sven Mahner and from AstraZeneca, Medac, PharmaMar, Roche, Tesaro by Fabian Trillsch. All other authors declare no conflict of interest.
Références
J Proteome Res. 2009 Feb;8(2):471-82
pubmed: 19072283
J Hematol Oncol. 2017 Jan 13;10(1):16
pubmed: 28086938
ACS Chem Biol. 2013;8(6):1271-82
pubmed: 23547795
FEBS Lett. 2000 May 4;473(1):47-52
pubmed: 10802057
Int J Biochem Mol Biol. 2011;2(4):303-8
pubmed: 22187664
Cancer Genomics Proteomics. 2017 01-02;14(1):35-51
pubmed: 28031236
Lancet. 2001 Jan 20;357(9251):176-82
pubmed: 11213094
Lupus. 2018 Jan;27(1):139-142
pubmed: 28728510
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Oncotarget. 2016 Feb 2;7(5):5598-612
pubmed: 26734996
J Hematol Oncol. 2015 Mar 08;8:22
pubmed: 25887760
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Gynecol Oncol. 2006 Jan;100(1):33-7
pubmed: 16153692
Cancer Res. 2009 Dec 15;69(24):9354-9
pubmed: 19934312
Obstet Gynecol. 2012 Sep;120(3):612-8
pubmed: 22914471
Hum Cell. 2017 Jul;30(3):226-236
pubmed: 28251557
Am J Epidemiol. 2006 Apr 1;163(7):670-5
pubmed: 16410346
Arthritis Rheum. 2011 Mar;63(3):654-61
pubmed: 21360494
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
FEBS J. 2011 Apr;278(7):1064-74
pubmed: 21261815
Oncotarget. 2015 Jun 20;6(17):15610-27
pubmed: 25951350
Front Cell Dev Biol. 2019 Apr 26;7:61
pubmed: 31106201
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Am J Psychol. 1987 Fall-Winter;100(3-4):441-71
pubmed: 3322052
J Biol Chem. 2005 Apr 8;280(14):14325-30
pubmed: 15805119
Exp Cell Res. 2015 Jul 15;335(2):216-23
pubmed: 26024773
Int J Med Microbiol. 2013 Dec;303(8):452-62
pubmed: 23906818
Autoimmun Rev. 2013 Jan;12(3):340-54
pubmed: 22743034
J Biol Chem. 2000 Feb 25;275(8):5958-65
pubmed: 10681589
Sci Rep. 2017 Mar 08;7:44186
pubmed: 28272459
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Oncol Rep. 2013 Apr;29(4):1322-32
pubmed: 23381546
Cell Mol Life Sci. 2001 Jun;58(7):902-20
pubmed: 11497239
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
FEBS J. 2007 Mar;274(6):1393-418
pubmed: 17302740
Genomics. 2004 Dec;84(6):1014-20
pubmed: 15533718
Diabetes Care. 2013 Nov;36(11):3405-10
pubmed: 23846809
Int J Med Microbiol. 2016 Jan;306(1):59-68
pubmed: 26679571
Stat Med. 2010 Dec 10;29(28):2946-55
pubmed: 20809485
Proteomics. 2005 Apr;5(6):1686-92
pubmed: 15800975
Mol Biol Cell. 2009 Dec;20(24):5127-37
pubmed: 19846662
Int J Mol Sci. 2019 Aug 14;20(16):
pubmed: 31416219
Obstet Gynecol. 1990 Feb;75(2):263-73
pubmed: 2300355
Proteomics. 2008 May;8(9):1744-9
pubmed: 18442176
J Biomed Biotechnol. 2012;2012:156795
pubmed: 23118496
Mol Carcinog. 2017 May;56(5):1427-1437
pubmed: 27996156
Biochemistry. 2007 Jul 24;46(29):8659-68
pubmed: 17595061
PLoS One. 2010 Sep 23;5(9):e12961
pubmed: 20886042
Int J Oncol. 2014 Aug;45(2):764-70
pubmed: 24841372
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
Mol Cancer. 2014 Mar 21;13:65
pubmed: 24650096
Virchows Arch. 2012 Mar;460(3):237-49
pubmed: 22322322
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Arthritis Res Ther. 2005;7(6):R1421-9
pubmed: 16277695
J Mol Endocrinol. 2009 Mar;42(3):249-60
pubmed: 19060179
Hum Cell. 2013 Jun;26(2):56-66
pubmed: 23504277
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679